Association of baseline HBcAg and HBV DNA with persistent detectability of HBV RNA during NA therapy
PLOS One · 02.07.2026 · 21 (7) · e0352870
DOI: 10.1371/journal.pone.0352870 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, online erschienen am 02.07.2026. Verfasst von Lanjie Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China. Hauptthemen laut MEDLINE: Hepatitis B virus, DNA, Viral, RNA, Viral, Hepatitis B, Chronic. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
Even after long-term nucleos(t)ide analogue (NA) therapy achieves hepatitis B virus (HBV) DNA suppression in patients with chronic hepatitis B (CHB), serum HBV RNA may remain detectable. HBV RNA reflects intrahepatic viral transcriptional activity. This study identified baseline traits and predictors of persistent HBV RNA positivity during NA therapy after sustained HBV DNA suppression.
Methods
This retrospective study included 155 CHB patients who underwent liver biopsy before initiating NA therapy, subsequently achieved sustained HBV DNA suppression on continuous NA therapy. Patients were classified into two groups according to HBV RNA status during therapy. Baseline clinical, virological and histological variables were assessed by multivariate logistic regression. Correlations between HBV RNA and serological markers were also assessed. The diagnostic performance of the model was analyzed using area under the receiver operating characteristic (AUC) and boostrap internal validation.
Results
Overall, 47.7% achieved undetectable serum HBV RNA. Higher baseline HBV DNA and absence of intrahepatic hepatitis B core antigen (HBcAg) independently predicted persistent HBV RNA positivity (both P < 0.001). The combined assessment of HBcAg with HBV DNA improved predictive accuracy (AUC = 0.780), outperforming either marker alone. The AUC value of bootstrap internal validation was 0.756. Across the cohort, HBV RNA showed moderate correlation with hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg) and hepatitis B e antibody (HBeAb). Correlations were minimal in HBeAg-negative patients and most evident in HBeAg-positive patients.
Conclusion
Incorporating HBcAg histology with baseline HBV DNA may enable more individualized treatment strategies during antiviral therapy. Correlations between HBV RNA and traditional markers are primarily observed in HBeAg-positive patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
- Department of Infectious Diseases, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
- Laboratory Medicine Center, Department of Clinical Laboratory, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
- Cancer Center, Department of Pathology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, Zhejiang, China.
- Shulan International Medical College, Zhejiang Shuren University, Hangzhou, Zhejiang, China.
ORCID-Profile: Hongying Pan
Zitieren
APA
Wu, L., Pan, Z., Yu, J., Yue, X., He, F., Yu, L., Pan, L., Wu, Y., Zhou, C., Yan, P., & Pan, H. (2026). Association of baseline HBcAg and HBV DNA with persistent detectability of HBV RNA during NA therapy. PLOS One, 21(7), e0352870. https://doi.org/10.1371/journal.pone.0352870
Vancouver
Wu L, Pan Z, Yu J, Yue X, He F, Yu L, et al. Association of baseline HBcAg and HBV DNA with persistent detectability of HBV RNA during NA therapy. PLOS One. 2026;21(7):e0352870. doi:10.1371/journal.pone.0352870
BibTeX
@article{Wu2026,
author = {Wu, Lanjie and Pan, Zixiang and Yu, Jianli and Yue, Xitan and He, Fang and Yu, Lili and Pan, Ling and Wu, Yuyan and Zhou, Chuntao and Yan, Peiye and Pan, Hongying},
title = {Association of baseline HBcAg and HBV DNA with persistent detectability of HBV RNA during NA therapy},
journal = {PLOS One},
year = {2026},
volume = {21},
number = {7},
pages = {e0352870},
doi = {10.1371/journal.pone.0352870}
}
EUVIMED